Table 1.
Baseline characteristics according to clinical outcome of 275 COVID-19 patients at IHU Méditerranée infection Marseille, France between 2020, March, 1st and 2020, April, 16th.
| Good outcome |
Poor clinical outcome |
Total |
|
|---|---|---|---|
| n (%) | n (%) | n (%) | |
| Groupe size | 200 (73%) | 75 (27%) | 275 (100%) |
| Age (years) | |||
| Mean (SD) | 49.4 (16.2) | 64.1 (14.6)∗∗∗ | 53.4 (17) |
| Median [Mean - Max] | 49 [18–89] | 63 [31–91] | 54 [18–91] |
| Sex ratio (M/F) | 0.74 | 1.34∗ | 0.87 |
| Time between diagnosis and Zn Level measurement | |||
| Mean (SD) | 2.61 (2.27) | 2.17 (2.4) | 2.5 (2.3) |
| Median [Mean - Max] | 2 [0–15] | 1 [0–9]∗ | 2 [0–15] |
| Clinical manifestations | |||
| Fever | 39 (19.5) | 28 (37.3)∗∗ | 67 |
| Cough | 71 (35.5) | 32 (42.7) | 103 |
| Rhinitis | 27 (13.5) | 8 (10.7) | 35 |
| Anosmia | 32 (16)∗ | 5 (6.67) | 37 |
| Agueusia | 26 (13) | 5 (6.67) | 31 |
| Dyspnea | 29 (14.5) | 14 (18.7) | 43 |
| Clinical classification (NEWS score) | |||
| 0–4 (low) | 182 (91)∗∗∗ | 31 (41.3) | 213 |
| 5–6 (medium) | 8 (4) | 14 (18.7)∗∗∗ | 22 |
| ≥7 (high) | 10 (5) | 30 (40)∗∗∗ | 40 |
| Evolution | |||
| Hospitalization | 63 (31.5) | 75 (100)∗∗∗∗ | 138 |
| Median days of hospitalization [Min - Max] | 4 [1–9] | 15 [1–40]∗∗∗∗ | |
| ICU | 0 (0) | 28 (37.3)∗∗∗∗ | 28 |
| Deaths | 0 (0) | 13 (17.3)∗∗∗∗ | 13 |
| Comorbidities | |||
| Hypertension | 45 (22.5) | 36 (48)∗∗∗ | 81 |
| Diabetes mellitus | 21 (10.5) | 21 (28)∗∗∗ | 42 |
| Obesity | 16 (8) | 13 (17.3)∗ | 29 |
| Cancer | 8 (4) | 12 (16)∗∗ | 20 |
| Coronary disease | 8 (4) | 12 (16)∗∗ | 20 |
| Zinc blood level | |||
| Mean (SD) | 1007 (240.8) | 841.1 (198.8) | 961.9 (241.4) |
| Median [Mean - Max] | 970.5 [627–3058]∗∗∗ | 840 [270–1326] | 947 [270–3058] |
| Therapeutics | |||
| HCQ+AZ | 178 (89)∗∗∗ | 46 (61.3) | 224 (81.5) |
| Other treatment | 22 (11) | 29 (38.7)∗∗∗ | 51 (18.5) |
The frequencies or the values found significantly higher when comparing the two groups are highlighted in bold.